Lyell Immunopharma, Inc. (LYEL) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in South San Francisco, CA, United States. The current CEO is Lynn Seely.
LYEL has IPO date of 2021-06-17, 300 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $544.69M.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
